Genentech Gazyva Shows Strong Results in Lupus Phase III Trial
November 3, 2025
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Genentech, a